Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Trill Impact in connection with the acquisition of ID North AB
Mandate

Vinge advises Trill Impact in connection with the acquisition of ID North AB

October 25, 2021 Corporate Commercial IT, Telecommunications and Outsourcing Intellectual Property M&A

Vinge advises Trill Impact in connection with the acquisition of ID North AB (”ID North”).

ID North operates within Identity Access Management and cyber security providing IT consulting services, resale and in-house development of IT products with its base in Stockholm. With an ambition to build a leading group that addresses the increasing need for cybersecurity services, the acquisition of ID North comprises one of two platform investments to the new group called European ID Security.

Vinge’s team consisted of Christina Kokko together with Karl Klackenberg, Desirée Hagenfeldt and Nina Gransäter (M&A), Åsa Gotthardsson and Carl Östlund (Employment), Sofia Bergenstråhle (IP), Alva Hägglund (Corporate Commercial), Karl-Hugo Engdahl (IT and GDPR), Tove Lövgren Frisk (Compliance) and Sara Dahlros Sköld (VDR assistant).

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

 Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

 Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

 Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026